Brief: Ultimovacs Announces Publication In The Journal Of Translational Medicine On Mechanistic Rationale Of Uv1 Cancer Vaccine Supporting Phase 2 Study Design In Malignant Mesothelioma
01/06/2021 14:05
June 1 (Reuters) - Ultimovacs ASA ULTIMO.OL :
* ULTIMOVACS ANNOUNCES PUBLICATION IN THE JOURNAL OF
TRANSLATIONAL
MEDICINE ON MECHANISTIC RATIONALE OF UV1 CANCER VACCINE
SUPPORTING PHASE 2 STUDY DESIGN IN MALIGNANT MESOTHELIOMA
Source text for Eikon: ID:nGNX1WRs0V
Further company coverage: ULTIMO.OL
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Zelluna ASA
See all newsNorway's Zelluna ASA reports Q2 loss
Brief: Zelluna Reports Q2 Total Loss Of NOK 19.7 Million
Brief: Zelluna Says IDMC Recommends Recruitment Of Next Two Patients At First Dose Level
Brief: Zelluna Says First Patient Dosed With Zi-Ma4-1 In Zima-101 Phase 1 Trial
Brief: Zelluna Wins NOK 16 Mln Research Council Of Norway Grant